Natalizumab
- Generic Name
- Natalizumab
- Brand Names
- Tysabri, Tyruko
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 189261-10-7
- Unique Ingredient Identifier
- 3JB47N2Q2P
- Background
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for mu...
- Indication
Natalizumab is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
...
- Associated Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Severe Crohn's Disease, Moderate Crohn’s Disease
- Associated Therapies
- -
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2002-02-18
- Last Posted Date
- 2009-06-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1200
- Registration Number
- NCT00030966
- Locations
- 🇺🇸
Mercy Hospital Outpatient Pharmacy, Des Moines, Iowa, United States
🇺🇸University of Pittsburgh, Department of Neurology, Pittsburgh, Pennsylvania, United States
🇩🇪Asklepios Klinik Schildautal, Seesen/Harz, Germany
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2001-12-03
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 900
- Registration Number
- NCT00027300
- Locations
- 🇬🇧
Oldchurch Hospital, Essex, United Kingdom
🇧🇪National MS Centrum, Melsbroek, Belgium
🇺🇸University of Miami School of Medicine, Department of Neurology, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.